香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《上海 復星醫藥（集團）股份有限公司公司債券募集資金管理制度（2025 年修訂）》，僅供參閱。 承董事會命 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 上海復星醫藥（集團）股份有限公司 董事長 第一章 总 则 第一条 为规范上海复星医药（集团）股份有限公司（以下简称"公司"） 公司债券募集资金管理和使用，根据《中华人民共和国公司法》《中华人民共 和国证券法》《公司信用类债券信息披露管理办法》《公司债券发行与交易管 理办法》以及《上海复星医药（集团）股份有限公司章 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《上海 復星醫藥（集團）股份有限公司投資者關係管理辦法（2025 年修訂）》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 投资者关系管理办法 （2025年修订） 第一章 总则 第一条 为规范上海复星医药（集团）股份有限公司（以下简称"公司"）投 资者关系管理工作，加强公司与投资者及潜在投资者（以下简称"投资者"）之 间的有效沟通，切实保护投资者特别是中小投资者合法权益，根据《中华人民共 和国公司法》《中华 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《上海 復星醫藥（集團）股份有限公司董事 ╱ 有關僱員進行證券交易的書面指引（2025 年修訂）》， 僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 陳玉卿 中國，上海 2025 年7 月1 5 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Peng ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 發起設立之私募股權投資基金進展暨關聯交易的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年7 月1 5 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《第十 屆董事會第三次會議（臨時會議）決議公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年7 月1 5 日 证券代码：600196 股票简称：复星医药 编号：临 2025-117 上海复星医药（集团）股份有限公司 第十届董事会第三次会议（临时会议）决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确 ...

Core Viewpoint - The company is progressing with the establishment of the Suzhou Angel Fund, which has undergone a capital reduction of RMB 76 million, reducing the total subscribed capital from RMB 176 million to RMB 100 million, while maintaining the ownership proportions of the partners involved [1][2][3]. Fundraising Situation - The Suzhou Angel Fund was established in January 2022 with a total subscribed capital of RMB 176 million, of which RMB 94.25 million has been paid in as of the announcement date [3][6]. - The fund's partners include the company through its subsidiary Ningbo Fuying, which has subscribed RMB 110 million (with RMB 61.25 million paid in), holding 62.50% of the fund [1][3]. Transaction Overview - The capital reduction was agreed upon by all partners due to the approaching end of the fund's investment period and the need for funds for investment plans, resulting in a total reduction of RMB 76 million [2][4]. - After the reduction, the subscribed capital of the Suzhou Angel Fund will be RMB 100 million, with the ownership proportions remaining unchanged [2][3]. Fund Basic Information - The Suzhou Angel Fund focuses on early-stage investments in the biopharmaceutical and healthcare sectors [6][7]. - As of the announcement date, the fund's total assets were RMB 99.14 million, with net assets attributable to partners at RMB 99.05 million [7]. Related Party Transactions - The capital reduction constitutes a related party transaction as one of the partners, Xing Sheng Fu Ying, is a subsidiary of the company's controlling shareholder, Fosun High Technology [2][4]. - The transaction has been approved by the company's board of directors and does not require shareholder approval [5][10].

Core Points - The document outlines the written guidelines for securities trading by employees of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, ensuring compliance with relevant laws and regulations [1][2][4] Group 1: General Provisions - The guidelines are established to regulate the trading behavior of employees regarding the company's securities, in accordance with the Company Law and Securities Law of the People's Republic of China [1] - Employees defined in the guidelines include those who may possess undisclosed price-sensitive information due to their positions [1] Group 2: Absolute Prohibitions - Employees are absolutely prohibited from trading company securities if they possess undisclosed price-sensitive information [2][7] - Strict self-discipline is required to avoid insider trading, false trading, market manipulation, and other illegal activities [2][7] Group 3: Other Trading Restrictions - Trading is restricted during specific periods, including 60 days prior to annual performance announcements and 30 days prior to quarterly or semi-annual announcements [2][11] - Directors and senior management are limited to transferring no more than 25% of their holdings annually, with specific conditions for newly acquired shares [14][15] Group 4: Notification and Reporting - Employees must submit a written notification to the board before trading company securities and cannot proceed without written confirmation [3][19] - The company must report any changes in securities holdings within two trading days, including details of the transactions [18] Group 5: Special Circumstances - In special circumstances, such as urgent financial obligations, the board may consider allowing prohibited trades, adhering to regulatory requirements [4][19] - The company must notify the stock exchange of any special circumstances surrounding the trading of securities [19]

Core Points - The document outlines the management and usage of funds raised through bond issuance by Shanghai Fosun Pharmaceutical (Group) Co., Ltd, ensuring compliance with relevant laws and regulations [1][8] - The company is required to establish a special account for the storage of raised funds, which must be used solely for the intended purposes and managed according to strict internal procedures [2][3][4] - The use of raised funds is primarily restricted to the company's main business activities, with specific prohibitions against financial investments and unauthorized changes in fund usage [5][6][7] Fund Management and Usage - The company must follow internal approval processes for all expenditures related to investment projects funded by raised capital, ensuring transparency and accountability [4][6] - Any changes to the intended use of raised funds must be approved by the board or authorized personnel, with necessary disclosures made to stakeholders [7][8] - The financial department is responsible for maintaining detailed records of fund usage and must report any irregularities to the trustee [15][16]

Core Viewpoint - The document outlines the investor relations management guidelines for Shanghai Fosun Pharmaceutical (Group) Co., Ltd., emphasizing the importance of effective communication with investors, particularly small and medium-sized investors, to enhance corporate governance and overall value [1][2]. Group 1: Principles of Investor Relations Management - Compliance Principle: Investor relations management must adhere to legal and regulatory requirements, ensuring transparency and ethical conduct [2]. - Equality Principle: All investors should be treated equally, with special provisions for small and medium-sized investors to participate [2]. - Proactivity Principle: The company should actively engage with investors, listening to their feedback and addressing their concerns promptly [2]. - Honesty and Integrity Principle: The company must maintain integrity and responsibility in its investor relations activities, fostering a healthy market environment [2]. Group 2: Responsibilities and Organization - Responsibilities: The company is tasked with drafting detailed investor relations management guidelines, organizing communication activities, handling investor inquiries and complaints, and maintaining relevant channels and platforms [5][6]. - Management Structure: The board of directors is responsible for decision-making in investor relations, with the chairman overseeing daily management through a designated department [3][4]. Group 3: Communication Content and Methods - Communication Content: The company should communicate information related to its development strategy, legal disclosures, operational management, environmental, social, and governance (ESG) information, and shareholder rights [8]. - Communication Channels: The company is encouraged to utilize multiple channels such as its official website, new media platforms, and direct communication methods like investor meetings and roadshows to engage with investors [5][6]. Group 4: Investor Meetings and Events - Investor Meetings: The company must hold investor meetings, including performance briefings and special sessions for significant events, ensuring that key personnel are present to address investor inquiries [10][11]. - Documentation: The company should maintain records of investor relations activities, including participant details, communication content, and any materials used during these events [12].

上海复星医药（集团）股份有限公司 公司债券募集资金管理制度 第三条 募集资金的使用和管理，应当履行公司的决策和审批程序。公司应 按约定用途使用募集资金，并根据相关法律法规的规定，及时披露募集资金使用 情况。如在存续期间改变或调整募集资金用途，应履行相关程序并及时披露。 （2025年修订） 第四条 公司董事、高级管理人员应当勤勉尽责，督促公司规范使用募集资 金，自觉维护募集资金的安全，不得参与、协助或纵容公司擅自或变相改变募集 资金用途。 第一章 总 则 第五条 在公司债券存续期间，存放募集资金的商业银行（以下简称"监管 银行"）、债券受托管理人对募集资金的管理和使用履行监督职责，公司应按照 《受托管理协议》《账户及资金监管协议》等约定及相关法律法规、本制度的规 定提供必要的支持和配合。 第一条 为规范上海复星医药（集团）股份有限公司（以下简称"公司"） 公司债券募集资金管理和使用，根据《中华人民共和国公司法》《中华人民共 和国证券法》《公司信用类债券信息披露管理办法》《公司债券发行与交易管 理办法》以及《上海复星医药（集团）股份有限公司章程》（以下简称"《公司 章程》"）的规定，特制定本制度。 1 第二条 本 ...